BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A by Puppe, Julian et al.
Open Access
Available online http://breast-cancer-research.com/content/11/4/R63
Page 1 of 12
(page number not for citation purposes)
Vol 11 No 4 Research article
BRCA1-deficient mammary tumor cells are dependent on EZH2 
expression and sensitive to Polycomb Repressive Complex 
2-inhibitor 3-deazaneplanocin A
Julian Puppe1,2, Rinske Drost3, Xiaoling Liu3,8, Simon A Joosse4, Bastiaan Evers3, 
Paulien Cornelissen-Steijger1, Petra Nederlof5, Qiang Yu6, Jos Jonkers3*, Maarten van Lohuizen1* 
and Alexandra M Pietersen1,7*
1Molecular Genetics and Cancer Genomics Centre, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
2Institute of Physiological Chemistry, The Medical Faculty Carl-Gustav Carus, Fetscherstraß 74, 01307 Dresden, Germany
3Division of Molecular Biology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
4Department of Experimental Therapy, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
5Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
6Molecular Pharmacology, Genome Institute of Singapore, 60 Biopolis Street, 138672 Singapore
7National Cancer Centre Singapore/Duke-NUS GMS, 11 Hospital Drive, 169610 Singapore
8Current address: Biomedical Analysis Center, Tsinghua University, Beijing 100084, PR China
* Contributed equally
Corresponding author: Jos Jonkers, j.jonkers@nki.nlMaarten van Lohuizen, m.v.lohuizen@nki.nlAlexandra M Pietersen, gmsamp@nus.edu.sg
Received: 31 May 2009 Revisions requested: 6 Jul 2009 Revisions received: 6 Aug 2009 Accepted: 26 Aug 2009 Published: 26 Aug 2009
Breast Cancer Research 2009, 11:R63 (doi:10.1186/bcr2354)
This article is online at: http://breast-cancer-research.com/content/11/4/R63
© 2009 Puppe et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
Abstract
Introduction Treatment of breast cancer is becoming more
individualized with the recognition of tumor subgroups that
respond differently to available therapies. Breast cancer 1 gene
(BRCA1)-deficient tumors are usually of the basal subtype and
associated with poor survival rates, highlighting the need for
more effective therapy.
Methods We investigated a mouse model that closely mimics
breast cancer arising in BRCA1-mutation carriers to better
understand the molecular mechanism of tumor progression and
tested whether targeting of the Polycomb-group protein EZH2
would be a putative therapy for BRCA1-deficient tumors.
Results Gene expression analysis demonstrated that EZH2 is
overexpressed in BRCA1-deficient mouse mammary tumors. By
immunohistochemistry we show that an increase in EZH2
protein levels is also evident in tumors from BRCA1-mutation
carriers. EZH2 is responsible for repression of genes driving
differentiation and could thus be involved in the undifferentiated
phenotype of these tumors. Importantly, we show that BRCA1-
deficient cancer cells are selectively dependent on their
elevated EZH2 levels. In addition, a chemical inhibitor of EZH2,
3-deazaneplanocin A (DZNep), is about 20-fold more effective
in killing BRCA1-deficient cells compared to BRCA1-proficient
mammary tumor cells.
Conclusions We demonstrate by specific knock-down
experiments that EZH2 overexpression is functionally relevant in
BRCA1-deficient breast cancer cells. The effectiveness of a
small molecule inhibitor indicates that EZH2 is a druggable
target. The overexpression of EZH2 in all basal-like breast
cancers warrants further investigation of the potential for
targeting the genetic make-up of this particular breast cancer
type.
BAC: bacterial artificial chromosome; BRCA1: breast cancer 1 gene; BSA: bovine serum albumin; DAB: diaminobenzidine; DMEM: Dulbecco's Mod-
ified Eagle Medium; DMSO: dimethyl sulfoxide; DZNep: 3-deazaneplanocin A; ER: estrogen receptor; EZH2: human homolog of the Drosophila 
enhancer of zeste gene; FCS: fetal calf serum; HER: human epidermal growth factor receptor; HRP: horseradish peroxidase; IC50: half maximal inhib-
itory concentration; KB1P: K14cre;Brca1F/F;p53F/F, cells derived from mammary tumors arising in mice with this genotype are BRCA1-deficient; KP: 
K14cre;Brca1w.t/w.t;p53F/F, cells derived from mammary tumors arising in mice with this genotype are BRCA1-proficient; PARP: Poly(ADP-ribose) 
polymerase; PBS: phosphate-buffered saline; PcG: Polycomb Group; PR: progesterone receptor; PRC2: Polycomb Repressive Complex 2; RT-PCR: 
reverse-transcription polymerase chain reaction; SCM: stem cell medium; siRNA: small interfering RNA; TSA: trichostatin A.Breast Cancer Research    Vol 11 No 4    Puppe et al.
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Introduction
Breast cancer is a heterogeneous disease. Studies by Perou
and colleagues and Sorlie and colleagues have demonstrated
that at least five different subtypes can be identified based on
molecular profiling [1,2]. These different subtypes might arise
from transformation of different cell types in the breast and/or
from mutations in different genes. It has become clear that
breast cancer subtypes correspond with marked differences
in therapy response and overall survival, indicating that each
subgroup should be treated differently [3]. To a certain extent
this is already common practice, as ErbB2-overexpressing
tumors are treated with herceptin and estrogen receptor (ER)-
positive tumors with tamoxifen or aromatase inhibitors [4].
However, for other groups, such as the basal-type tumors that
lack expression of ErbB2, ER, and progesterone receptor
(PR), rationally designed treatments are currently lacking.
These tumors are generally characterized by a poor differenti-
ation grade, and it is speculated that they may arise from an
undifferentiated breast epithelial cell, or at least have acquired
stem cell-like properties during transformation [5]. Currently,
standard treatment of these tumors is chemotherapy. Although
there is an initial effect of chemotherapy agents such as
anthracyclins, basal-like tumors nevertheless exhibit the worst
overall survival rate of all breast cancer subtypes. This high-
lights the need for more effective therapies.
In the current study, we investigated the potential of a molec-
ular-based therapy for a subgroup of basal-like breast tumors:
those arising in women with an inherited mutation in BRCA1.
These tumors are characterized by the loss of the second
BRCA1  allele, concomitant loss of TP53  function and an
undifferentiated, basal-like phenotype [6-9]. Consistent with
their basal-like characteristics, BRCA1-deficient breast
tumors exhibit aggressive behavior and are associated with
poor survival. At the cellular level, an important consequence
of loss of BRCA1 function is impaired DNA double-strand
break repair [10]. As unresolved double-strand breaks will
activate p53, resulting in either cell cycle arrest or apoptosis,
there is a strong selection pressure on loss of p53 function in
BRCA1-associated breast tumorigenesis. In addition, recent
evidence indicates that loss of BRCA1 inhibits differentiation
into ER-positive luminal cells, which might contribute to the
undifferentiated phenotype [11].
We developed a mouse model mimicking human BRCA1-defi-
cient breast cancer to gain insight into the molecular progres-
sion of BRCA1-deficient tumors and to test putative therapies
[12]. In this model, the Brca1 and p53 genes are deleted by
tissue-specific expression of Cre recombinase driven by the
keratin 14 promoter, which is active in basal cells of the mam-
mary gland, including the stem cells [13]. The ensuing mam-
mary tumors show a solid growth pattern with pushing
margins, and are highly proliferative, poorly differentiated and
similar to human basal-like breast cancers (ER-, PR- and
human epidermal growth factor receptor (HER) 2-negative).
Importantly, our mouse model allows us to compare BRCA1-
deficient mammary tumors (arising in K14cre;Brca1F/F;p53F/F
(KB1P) mice) with BRCA1-proficient control tumors (arising in
K14cre;Brca1w.t/w.t;p53F/F (KP) mice). After comparing gene
expression patterns of BRCA1-deficient mouse mammary
tumors with BRCA1-proficient control tumors, we noted that
Ezh2  expression was particularly high in BRCA1-deficient
tumors. EZH2 is a member of the family of polycomb group
proteins, which are epigenetic repressors that prevent the
expression of cell cycle inhibitors and genes required for dif-
ferentiation [14,15]. We and others have already observed
that EZH2 overexpression is linked to aggressive tumours with
a high proliferation rate and a poor prognosis [16-20].
In the study presented here, we set out to determine whether
increased EZH2 expression also characterizes human
BRCA1-deficient breast cancer, and whether BRCA1-defi-
cient tumor cells are dependent on high EZH2 levels for their
survival. This would indicate that EZH2 constitutes a therapeu-
tic target for BRCA1-deficient breast cancer. EZH2 is the cat-
alytic subunit of Polycomb Repressive Complex 2 (PRC2),
which also contains SUZ12 and EED, and initiates gene
silencing by trimethylating lysine 27 in histone H3 (H3-
K27me3) [21]. Tan and colleagues recently demonstrated that
a small molecule inhibitor, 3-deanzaneplanocin A (DZNep),
effectively reduced the protein levels of PRC2 components
EZH2, SUZ12, and EED, and inhibits the associated H3K27
trimethylation activity [22]. H3-K27me3 depletion resulted in
reactivation of PRC2-silenced genes and apoptotic cell death
in several cancer cell lines. The availability of a small molecule
inhibitor such as DZNep allowed us to test whether pharma-
cological targeting of EZH2 function provides a selective
approach to kill BRCA1-deficient breast tumor cells.
Materials and methods
Derivation and maintenance of mouse tumor cell lines
Tumor cell lines were generated from individual tumors arising
in female mice with a KB1P or KP genotype as described pre-
viously [23]. Established cell lines were cultured at 37°C with
5% carbondioxide in DMEM-F12 medium (Gibco, Carlsbad,
CA, USA) supplemented with 10% FCS, 50 U/ml penicillin,
50 μg/ml streptomycin (Gibco, Carlsbad, CA, USA), 5 μg/ml
insulin (Sigma, St. Louis, MO, USA), 5 ng/ml epidermal growth
factor (Invitrogen, Carlsbad, CA, USA) and 5 ng/ml cholera
toxin (Gentaur, Brussels, Belgium).
BRCA1 reconstitution in BRCA1-deficient tumor cells
One million KB1P3.12 cells were electroporated (3 μF, 0.8
kV) with the bacterial artificial chromosome (BAC) clone
RP11-812O5 containing the complete human BRCA1 gene
and regulatory sequences. The RP11-812O5 BAC was
obtained from the Children's Hospital and Research Center at
Oakland, CA, USA [24]. The vector backbone was modified
by insertion of the pgk/EM7 Neo/KanR-positive selection cas-
sette pCEI1 [25] into the sacBII gene by bacterial homologousAvailable online http://breast-cancer-research.com/content/11/4/R63
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recombination in Escherichia coli SW102 [26]. After selection
with 300 μg/ml Geneticin (Gibco-BRL, Carlsbad, CA, USA)
for two weeks, clones were picked and checked for the pres-
ence of the BAC by PCR for exon 11 of human BRCA1 [27].
Tumorsphere formation assay
Stem cell medium (SCM) containing defined growth factors as
described by [28,29] was freshly prepared each time and
DZNep (5 μm) or dimethyl sulfoxide (DMSO; no-drug control)
was added. Cells were trypsinized, which was inactivated with
10% serum and subsequently washed with PBS to remove
the serum, and resuspended in SCM. Cells were filtered to
obtain single cells and 40,000 cells, counted with a Casy
counter (Schaerfe Systems, Reutlingen, Germany), were
plated out in ultra-low binding plates with a flat bottom (Corn-
ing Incorporated, Corning, NY, USA). Sphere formation was
checked every day and cell culture images were obtained after
72 hours using a Zeiss Axiovert 25 microscope (Carl Zeiss
MicroImaging, Goettingen, Germany) with 10× objective on a
Sony Cybershot (Sony corporation, Tokyo, Japan).
Classification of human breast tumor samples
Human breast tumor tissue samples were obtained from the
pathology archive of the Netherlands Cancer Institute.
BRCA1-mutation status was determined by routine DNA diag-
nostics. The basal-like and luminal status was determined
using expression data to classify the tumors according to the
intrinsic gene set as described [30].
Immunohistochemistry
Paraffin-embedded tumor samples were sectioned (4 μm) and
deparaffinized by treating twice with xylene for 10 minutes
each and subsequently hydrated in 100%, 80%, and 70% eth-
anol. Antigen retrieval was performed by boiling samples in 10
mM sodium citrate for one minute at 900 W and 15 minutes at
250 W in the microwave, followed by 20 minutes gradual cool-
ing at room temperature. Slides were blocked in 5% normal
goat serum in PBS. Mouse tissue was additionally permeabi-
lized with 0.25% Triton prior to blocking. The samples were
incubated overnight with a mouse monoclonal antibody
against EZH2 (1:100, BD Biosciences San Jose, California,
USA). Immunodetection was performed by diaminobenzidine
(DAB) oxidation using the Powervision system (ImmunoLogic,
Duiven, The Netherlands). Samples were dehydrated in 70%,
80%, and 100% ethanol. Once immunostained, slides were
digitally scanned with a Scanscope (Aperio Technologies,
Vista, CA, USA) and the amount of EZH2-expressing epithelial
cell nuclei were counted in a blinded manner by two observers
(SAJ and JP) independently. For statistical analysis, the Wil-
coxon test was used to compare the percentage of EZH2-pos-
itive nuclei between two samples and P  < 0.05 was
considered statistically significant.
Immunoblot analysis
Cells were scraped from subconfluent plates and lysed in
RIPA buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.5, 1% Triton
X100, 1% DOC, 0.1% SDS, 1 mM EDTA) Equal amount of
protein (10 μg) was loaded and separated by electrophoresis
on NuPAGE Novex 4 to 12% SDS-PAGE (Invitrogen,
Carlsbad, CA, USA) and transferred to nitrocellulose mem-
branes. The blot was blocked with TBST (0.1% Tween 20)
containing 5% BSA (Sigma-Aldrich, St. Louis, MO, USA) and
incubated with primary antibodies for two hours at room tem-
perature. After washing with TBST, the membrane was incu-
bated with a horseradish peroxidase (HRP)-conjugated
secondary antibody and the signal was detected with
enhanced chemiluminescence substrate (GE Healthcare,
Amersham, UK). Following antibodies were used: mouse mon-
oclonal against EZH2 (1:20, provided by K. Helin), β-tubulin
(1:10000, Sigma-Aldrich, St. Louis, MO, USA), anti-mouse
IgG-HRP (1:10000, Biosource International, Camrillo, CA,
USA).
Quantitative real-time PCR
Total RNA was extracted using Trizol Reagent (Invitrogen,
Carlsbad, CA, USA) and 1 μg per sample was treated with
DNase. Reverse transcription was performed using the Super-
Script™ First-Strand Synthesis System for RT-PCR (Invitro-
gen, Carlsbad, CA, USA; according to manufacturer's
protocol). The generated cDNA was analyzed using SYBR
Green (Taqman universal PCR master mix, Applied Biosys-
tems, Foster City, CA, USA), performed on an ABI Prism 7000
SDS (Applied Biosystems, Foster City, CA, USA). Product
accumulation was evaluated using the comparative CT method
(DDCT), with Hprt levels as internal control for normalization.
The following primers were used (all for mouse transcripts):
Hprt  FW: CTGGTGAAAAGGACCTCTCG;  Hprt  RV:
TGAAGTACTCATTATAGTCAAGGGCA,  Ezh2  FW: AAA-
GACCCTGAATGCAGTCGC; Ezh2 RV: TGATCCAGAACT-
TCATCCCCC.
Microarray analysis
Expression values (Log2 ratio) of Ezh2 in 21 KB1P and 32 KP
mammary tumors were obtained from oligonucleotide microar-
rays representing 18,173 genes. Methods for RNA extraction,
RNA amplification, microarray hybridization, and data process-
ing are described by Liu and colleagues [12]. For comparison
of EZH2 gene expression (Log10 ratio) signatures between
mouse and human breast tumors, we used the expression pro-
files of 96 human breast tumors: 18 ER-negative BRCA1
tumors, 34 tumors with a good prognosis signature and 44
tumors with a poor prognosis signature categorized by the
human 70-genes signature dataset [31].
Growth inhibition assays
DZNep was provided by YU Qiang (Genome Institute of Sin-
gapore) and trichostatin A (TSA) was obtained from Sigma-
Aldrich (St. Louis, MO, USA). Both compounds were solved inBreast Cancer Research    Vol 11 No 4    Puppe et al.
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DMSO and stored at -20°C. Before the growth inhibition
assays, growth curves were made of all cell lines to determine
the amount of cells that ensure exponential growth during a
five-day culture period. For cell viability analysis, subconfluent
dishes were trypsinized and filtered to obtain single cells. Cells
were counted with a Casy counter and appropriate amounts
of cells were typically plated out in 96-well plates on day 0.
Drugs were added in twofold serial dilutions on day 1 in tripli-
cate. DMSO was used as a no-drug control. Both drugs were
left on the cells for 120 hours. On day 5 cell viability was meas-
ured using the Cell Titer Blue assay (Promega, Madison, WI,
USA). Cell Titer Blue reagent was added directly to the cells
(10 μl/well) and incubated for two hours at 37°C. Fluores-
cence at 560ex/590em nm was measured using a Tecan infinite
m200 plate reader (Tecan, Salzburg, Austria). After correction
for medium only and no-drug controls, data points were fitted
to a sigmoidal dose-response curve with variable slope using
GraphPad Prism Version 5.00 (GraphPad Software, San
Diego, CA, USA): Y = 100/(1 + 10^((LogIC50-X)*HillS-
lope))). At least three independent experiments were used to
determine the half maximal inhibitory concentration (IC50) val-
ues for each drug/cell line combination.
RNA interference and DZNep-drug treatment
The SMARTpool small interfering RNA (siRNA) targeting Ezh2
and the non-targeting control were purchased from Dhar-
macon (Lafayette, CO, USA). Prior to all knock-down experi-
ments optimal transfection conditions were determined for all
cell lines. Cells were plated on day 0 and either transfected
with 2 μM siRNA using DharmaFECT transfection reagent
according to manufacturer's protocol (Dharmacon, Lafayette,
CO, USA) or supplied with 5 μM DZNep on day 1. For protein
and RNA analysis cells were harvested 48, 72 and 96 hours
after transfection. The effect on cell growth was quantified
using a Cell Titer Blue cell viability assay as described above.
Cells were plated on day 0 in a density to allow exponential
growth during the whole experiment and either transfected
with siRNA or treated with 5 μM DZNep on day 1. Fluores-
cence was recorded 24, 48, 72 and 96 hours after transfec-
tion. Cell culture images were obtained using a Zeiss Axiovert
25 microscope with 10× objective on a Sony Cybershot. In all
cases, data are presented from at least three independent
experiments.
Results
Ezh2 expression is elevated in BRCA1-deficient mouse 
mammary tumors
To define the molecular changes associated with BRCA1-
deficient breast cancer, we previously compared BRCA1-defi-
cient (KB1P) mammary tumors derived from our conditional
K14cre;Brca1F/F;p53F/F mouse model for hereditary breast
cancer with BRCA1-proficient mammary tumors (KP) derived
from K14cre;Brca1w.t/w.t;p53F/F mice. Gene expression micro-
array analysis showed that KB1P tumors expressed markers of
basal-like breast cancer, for example p63 and keratin 5, com-
pared with the KP tumors [12,32]. Strikingly, the polycomb
repressor EZH2 is also higher expressed in BRCA1-deficient
tumors than in BRCA1-proficient control tumors (Figure 1a).
Whereas there is heterogeneity in the BRCA1-proficient
group, virtually all BRCA1-deficient tumors display increased
Ezh2 expression, suggesting that in the absence of BRCA1
increased levels of EZH2 may be required. To determine
whether the increase in mRNA levels translates to higher
EZH2 protein expression, we analyzed tissue sections from
both KB1P and KP tumors by immunohistochemistry (Figure
1b). We indeed found that BRCA1-deficient mouse mammary
tumors have higher EZH2 protein levels than control tumors,
also indicated by the higher percentage of tumor cells with
EZH2 expression above background (77% in KB1P tumors
versus 11.5% in KP tumors; Wilcoxon P < 0.029; Figure 1c).
EZH2 is overexpressed in BRCA1-deficient human breast 
tumors
Next, we determined whether EZH2 is also overexpressed in
human BRCA1-deficient breast cancer. Recently, we and oth-
ers showed that EZH2 levels are high in breast tumors with a
poor prognosis [16,18,33]. Tumors from BRCA1-mutation
carriers belong to this group of aggressive breast cancer, and
accordingly  EZH2 mRNA levels are also high in human
BRCA1-deficient tumors (Figure 2a). Consistent with our pre-
vious observation that EZH2 mRNA and protein levels corre-
late relatively well [16], we observed increased EZH2 protein
levels in human BRCA1-deficient tumor sections compared
with other breast tumors (Figure 2b). To allow direct compari-
son, we simultaneously performed immunohistochemistry for
EZH2 on sections from luminal A, basal-like and BRCA1-
mutated breast tumors. As previously reported [16,18,33], we
found EZH2 levels to be higher in basal-like tumors compared
with luminal A-type tumors (Figure 2b). By the same detection
criteria, EZH2 levels in the BRCA1-deficient tumors were at
least as high as in the sporadic basal-like tumors (no signifi-
cant difference, Wilcoxon P  < 0.164) and significantly
increased compared with luminal A-type tumors (Wilcoxon P
< 0.002, Figure 2c).
BRCA1-deficient cells are dependent on EZH2
To determine whether the increased EZH2 levels are function-
ally relevant in the BRCA1-deficient tumor cells, we made use
of cell lines that were derived from KB1P and KP mouse mam-
mary tumors [23]. In total, we used a panel of three BRCA1-
deficient and three BRCA1-proficient cell lines, all derived
from individual primary tumors. Although DZNep is a selective
inhibitor of EZH2 function, some effects on other epigenetic
marks, such as H4K20 methylation, have been reported [22].
To ascertain whether observed effects with DZNep are due to
its inhibition of EZH2 specifically, we included siRNAs target-
ing Ezh2 in our experiments.
Quantitative PCR demonstrated efficient knockdown of Ezh2
mRNA levels in both BRCA1-proficient and BRCA1-deficientAvailable online http://breast-cancer-research.com/content/11/4/R63
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cells (Figure 3a). DZNep does not affect Ezh2 mRNA levels,
as reported previously [22]. However, treatment with either
Ezh2-specific siRNAs or DZNep resulted in significant reduc-
tion of EZH2 protein levels in both KB1P and KP cells (Figure
3b). Forty-eight hours after treatment there was visible toxicity
in KB1P cells when EZH2 levels were reduced by either
DZNep or siRNAs targeting Ezh2, but not in KB1P cells
treated with non-targeting control siRNAs (Figure 3c). In con-
trast, there was no apparent effect of reduced EZH2 levels,
either by Ezh2 knock-down or DZNep treatment, in BRCA1-
proficient tumor cells. A more quantitative assessment of the
effect of the treatments by a growth inhibition assay revealed
that there is some adverse affect of DZNep in the KP cells.
However, this effect of DZNep is unrelated to EZH2, as knock-
down of Ezh2 does not inhibit the growth of these cells (Figure
3d, blue lines). Possibly, this is due to the effect of DZNep on
H4K20 or other methylation events. In contrast, KB1P cells
are severely affected by reduced EZH2 levels, as demon-
strated by a strong growth inhibition of KB1P cells treated with
siRNAs targeting Ezh2 (Figure 3d, red lines). In BRCA1-defi-
cient cells, treatment with DZNep inhibited growth even more
effectively than knock-down of Ezh2, which could be due to a
more effective depletion of EZH2 by DZNep than that
achieved by siRNAs, or due to possible effects of DZNep on
Figure 1
Ezh2 expression is elevated in BRCA1-deficient primary mouse mammary tumors Ezh2 expression is elevated in BRCA1-deficient primary mouse mammary tumors. (a) mRNA levels of Ezh2 in BRCA1-deficient (K14cre;Brca1F/
F;p53F/F (KB1P)) and BRCA1-proficient (K14cre;Brca1w.t/w.t;p53F/F (KP)) mammary tumors analyzed by microarray analysis. The mean (± standard 
error of the mean) log2 ratio of Ezh2 expression in 21 KP tumors is -0.036 (± 0.067) and 0.497 (± 0.054) in 32 KB1P tumors. The Ezh2 expression 
is significantly higher in KB1P tumors compared with KP tumors (*Wilcoxon exact test). (b) EZH2 protein levels in two independent primary KB1P 
and in two independent primary KP tumors detected by immunohistochemistry (scale bar represents 100 μm), representative of a total of four 
tumors analysed for each genotype. (c) Quantification of EZH2 immunohistochemistry shown in b (* Wilcoxon exact test).Breast Cancer Research    Vol 11 No 4    Puppe et al.
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other epigenetic marks. Nevertheless, DZNep shows remark-
able selectivity in inhibiting BRCA1-deficient tumor cells com-
pared with BRCA1-proficient tumor cells (Figures 3c, d).
BRCA1-deficiency sensitizes cells to EZH2-inhibitor 
DZNep but not to TSA
To better quantify the difference in sensitivity to DZNep
between KB1P and KP cells, we performed a dose-response
curve (Figure 4a). Strikingly, the average IC50 for BRCA1-defi-
cient cells is 163 nM, whereas an almost 19-fold higher dose
is required for 50% growth inhibition in BRCA1-proficient
cells (average IC50 of 2944 nM, P < 0.0001, t-test; Table 1).
To exclude the possibility that KB1P cells are in general more
sensitive to epigenetic inhibitors we tested the effect of the
histone deacetylase-inhibitor TSA in the same growth inhibi-
tion assay (Figure 4b). TSA affected KB1P and KP cell lines to
a similar extend (average IC50 of 26 nM vs 29 nM) showing no
significant difference (P = 0.5; t-test, Table 1). When the cell
lines were grown under non-adherent conditions, DZNep also
inhibited sphere-formation, suggesting that there is no sub-
population of BRCA1-deficient cells that is resistant to DZNep
treatment [see Additional data file 1]. However, in vivo experi-
ments should demonstrate whether targeting EZH2 inhibits all
tumor-initiating potential.
Reconstitution of BRCA1 partially restores resistance to 
DZNep
As loss of BRCA1 function results in genomic instability, we
wanted to establish whether the dependence on EZH2 is a
direct consequence of Brca1 loss, or whether this is a second-
ary effect caused by mutations accumulated during the tumor-
igenic process. To test this, we re-introduced a BAC clone
encompassing the complete human BRCA1  gene into a
BRCA1-deficient cell line (KB1P-3.12) and derived several
clones that were shown to re-express BRCA1 (Figure 5a).
These cells became less sensitive to cisplatin treatment indi-
cating that the introduced BRCA1 is functional (data not
shown). Of note, we did not observe a decrease in EZH2 lev-
els in the reconstituted cell lines, indicating that BRCA1 does
not directly influence Ezh2 expression (Figure 5b). However,
treatment with DZNep reduces EZH2 levels to a similar extent
in all cell lines (Figures 3b and 5d, and data not shown).
Interestingly, when the reconstituted cell lines were treated
with DZNep, we observed a substantial rescue from DZNep-
Figure 2
EZH2 is overexpressed in BRCA1-deficient human breast tumors EZH2 is overexpressed in BRCA1-deficient human breast tumors. (a) The mean (± standard error of the mean) log10 ratio of EZH2 expression in 
human breast cancer samples [45] is -0.15 (± 0.041; >five-year survival, good prognosis), 0.028 (± 0.046; <five-year survival, poor prognosis) and 
0.177 (± 0.047; BRCA1-deficient). EZH2 expression is significantly different between the three groups (* Kruskall-Wallis test). (b) Immunohisto-
chemistry for EZH2 in human breast tumor tissues (scale bar represents 100 μm). Two examples are shown of individual tumors for each subtype, 
representative of a total of six tumors analysed per subtype. (c) Quantification of EZH2 immunohistochemistry shown in b (* Wilcoxon exact test).Available online http://breast-cancer-research.com/content/11/4/R63
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Figure 3
EZH2 is required for survival of BRCA1-deficient but not BRCA1-proficient tumors cells EZH2 is required for survival of BRCA1-deficient but not BRCA1-proficient tumors cells. (a) Ezh2 mRNA expression measured by quantitative RT-
PCR in BRCA1-deficient cells (in red, K14cre;Brca1F/F;p53F/F (KB1P)) and in BRCA1-proficient cells (in blue, K14cre;Brca1w.t/w.t;p53F/F (KP)) after 
treatment with siRNAs against Ezh2 or 5 μM 3-deazaneplanocin A (DZNep; shown as fold induction relative to Hprt). (b) EZH2 levels analysed by 
western blot after KB1P and KP cells were treated with siRNAs targeting Ezh2 or non-targeting siRNAs (siNTC) and 5 μM DZNep or vehicle (dime-
thyl sulfoxide (DMSO)) for the indicated period. (c) Phase-contrast images of BRCA1-deficient and BRCA1-proficient cells treated for 48 hours with 
control (ctrl) siRNAs, siRNAs against Ezh2 or 5 μM DZNep (original magnification 10×). (d) Growth curves of KB1P (depicted in red) and KP cell 
lines (depicted in blue) treated with control (ctrl) siRNAs, siRNAs against Ezh2 or 5 μM DZNep. Data measured by Cell Titer Blue and represented 
as the mean ± standard error of the mean (three independent experiments). The depicted cell lines are representative for all three KB1P and KP cell 
lines.
Figure 4
Chemical EZH2-inhibitor DZNep selectively kills BRCA1-deficient tumor cells Chemical EZH2-inhibitor DZNep selectively kills BRCA1-deficient tumor cells. (a) Representative growth inhibition curves for BRCA1-deficient cell 
lines (K14cre;Brca1F/F;p53F/F (KB1P), in blue) and BRCA1-proficient cell lines (K14cre;Brca1w.t/w.t;p53F/F (KP), in red) treated with 3-dea-
zaneplanocin A (DZNep). A serial dilution of DZNep was added to the cells and cell viability was measured five days later (each data point repre-
sents the mean ± standard error of the mean (SEM) of three independent experiments). (b) Representative growth inhibition curves for BRCA1-
deficient cell lines (KB1P, in blue) and BRCA1-proficient cell lines (KP, in red) treated with trichostatin A (TSA). A serial dilution of TSA was added 
to the cells and cell viability was measured five days later (mean ± SEM).Breast Cancer Research    Vol 11 No 4    Puppe et al.
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induced cell death (Figure 5c). The IC50 values for DZNep in
the BRCA1-reconstituted cells lines were more similar to the
IC50 values of the KP cells, than those of KB1P cells (average
IC50 of 1391 nM, Table 2). This shows that sensitivity of
BRCA1-deficient cells to DZNep is mainly due to a loss of
BRCA1 function, and not due to secondary mutations. This
also indicates that there is a synthetic lethal effect; the effect
of targeting one gene (e.g. EZH2) becomes deleterious spe-
cifically in the absence of another gene (e.g. BRCA1) [34].
Although the reconstituted cells become over eight-times
more resistant to DZNep, the rescue is not complete. This
could be due to differences in mouse and human BRCA1 or
to technical issues with achieving the correct amount of
BRCA1 expression. Alternatively, additional mutations could
play a minor role in the sensitivity to DZNep.
In summary, we have demonstrated that DZNep selectively
inhibits BRCA1-deficient but not BRCA1-proficient mammary
tumor cells, and that this effect is mainly due to the fact that
BRCA1-deficient cells are dependent on EZH2, whereas
BRCA1-proficient cells are not.
Discussion
Breast tumors in BRCA1-mutation carriers arise early in life
and exhibit an aggressive, basal-like phenotype associated
with poor overall survival. More insight into the molecular
make-up of this breast cancer subtype will contribute to the
development of more effective therapies. In this study, we
demonstrate that EZH2 expression is high in breast tumors
from BRCA1-mutation carriers, similar to that observed in our
mouse model for BRCA1-deficient breast cancer. Moreover,
the knock-down experiments show that BRCA1-deficient
mammary tumor cells are dependent on EZH2 for their sur-
vival. Interestingly, although EZH2 levels were also reduced to
a similar level in the BRCA1-proficient control cells, these cells
seem much less affected by EZH2 loss. This indicates that tar-
geting EZH2 is synthetic lethal in combination with BRCA1-
deficiency. Conceivably, the dependence on high EZH2 levels
derives from a selective advantage during the in vivo tumori-
genesis process that occurs only in BRCA1-deficient and not
BRCA1-proficient cells. The observation that restoration of
BRCA1 does not reduce EZH2 levels suggests that the
increased expression is caused by more permanent changes.
However, such mutations or epigenetic alterations do not nec-
essarily have to target Ezh2  directly, but could occur in
upstream regulators of EZH2 as well. Note that selection for
Ezh2 overexpression may occur in other breast tumors, as evi-
dent from some of the primary BRCA1-proficient mouse
tumors in Figure 1a. The central question of this study was
whether overexpression of EZH2 is required for the survival of
breast tumor cells or whether this is a byproduct of the tumor-
igenic process, and our data suggest that whereas BRCA1-
deficient cells remain dependent on their EZH2 expression,
loss of EZH2 is much better tolerated in cells with intact
BRCA1.
Now that we have established the functional importance of
EZH2 expression in BRCA1-deficient cells, it would be inter-
esting to understand why these tumors are selectively depend-
ent on EZH2, and whether this dependence is specific to loss
of BRCA1 function, or more related to the basal-like character-
istics of these tumors. There could be several, not mutually
exclusive, reasons for selection of EZH2/Ezh2 overexpression
during tumorigenesis.
With regards to a specific role of BRCA1-deficiency, there
could be an effect of EZH2 on DNA repair. It has been
reported that EZH2 overexpression represses genes of the
Rad51 family [35], which may attenuate DNA damage signal-
ling in BRCA1-deficient cells. This would suggest that EZH2
overexpression could play a similar role in BRCA2-deficient
tumors that are subject to the same impairment in homology-
directed double-strand break repair as BRCA1-deficient
tumors. However, we did not observe increased EZH2 expres-
sion in breast tumors from BRCA2-mutation carriers (data not
shown), suggesting that the main oncogenic role of EZH2 is
not linked to DNA repair. Another possible explanation for the
selective overexpression of EZH2 in BRCA1-deficient breast
tumors could involve a role of EZH2 in the cell of origin. Spe-
cifically, the absence of BRCA1 has been associated with
characteristics of stem cells and loss of BRCA1 is incompati-
ble with luminal differentiation [11]. EZH2 is required for the
maintenance of embryonic and adult stem cells, is expressed
in a relatively small number of cells in the mammary gland, and
Table 1
IC50 values of DZNep and TSA on BRCA1-proficient vs. BRCA1-
deficient mammary tumor cells
Cell line nM DZNep (SEM) nM TSA (SEM)
BRCA1-proficient
KP-3.33 3202 (284) 27 (1.2)
KP-6.3 3467 (277) 35 (1.5)
KP-7.7 2163 (63) 25 (3.8)
BRCA1-deficient
KB1P-3.12 154 (14) 26 (2.4)
KB1P-30.3 163 (13) 17 (0.6)
KB1P-40.1 171 (9) 36 (3.4)
Ratio (KP/KB1P) 18.1* 1.1
Significance < 0.0001 0.5
Note: Values between brackets represent the standard error of the 
mean (SEM) of at least three independent experiments. Ratio: 
Average half maximal inhibitory concentration (IC50) values of 3-
deazaneplanocin A (DZNep) and trichostatin A (TSA) for the 
K14cre;Brca1w.t/w.t;p53F/F (KP) lines were compared with average 
IC50 values of the K14cre;Brca1F/F;p53F/F (KB1P) lines. 
*Significance: P < 0.01 (t-test).Available online http://breast-cancer-research.com/content/11/4/R63
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is only overexpressed in breast tumors with an undifferentiated
phenotype [16,19,36]. In addition, a large subset of genes
silenced by EZH2 includes transcription factors that orches-
trate lineage-specific differentiation [37,38]. Therefore, it
could be envisaged that overexpression of EZH2 is required
to maintain the undifferentiated state of the transformed cell.
Reducing EZH2 levels by DZNep or siRNAs might result in the
expression of genes that induce differentiation, a fate poten-
tially incompatible with the absence of BRCA1.
However, overexpression of EZH2 does not seem to cause
hyperrepression of typical PcG-target genes [16,39], sug-
gesting that it has consequences distinct from silencing its
normal target genes. Several groups have indeed found evi-
dence for genes marked by PcG proteins specifically in tumor
cells [22,40]. It remains to be established, however, whether
silencing of these genes is responsible for the selective advan-
tage of EZH2 overexpression in BRCA1-deficient tumor cells,
and whether these genes include more classical tumor-sup-
pressors or specific differentiation factors.
The model for a specific function of EZH2 in more undifferen-
tiated, basal-like cells is consistent with the observation that
our KB1P tumors are indeed more basal than the KP control
tumors [12]. This raises the question if not only BRCA1-defi-
cient breast tumors but also sporadic basal-like tumors would
be dependent on EZH2 overexpression. Our observation that
restoration of BRCA1 function negates the sensitivity of tumor
cells to DZNep would argue against this. However, although
BRCA1 mutations in sporadic cancer are rare, there are indi-
cations that a significant proportion of sporadic breast tumors
share traits with BRCA1-deficient tumors, a feature termed
BRCAness [41]. Alterations in genes functioning in the same
biochemical pathways as BRCA1 could effectively result in
loss of BRCA1 function [9]. Sporadic basal-like tumors that
exhibit this feature may be specifically sensitive to EZH2 inhi-
bition. Recently, Gonzalez and colleagues [42] showed that
knock-down of EZH2 reduced the proliferation of two ER-neg-
ative human breast cancer cell lines. Intriguingly, this effect
seemed partly due to an upregulation of BRCA1 protein levels.
This is in disagreement with our data which show that cells
without BRCA1 are particularly sensitive to EZH2 reduction,
suggesting that repression of Brca1 is not the main oncogenic
Figure 5
Restoration of BRCA1 partially rescues from sensitivity to DZNep Restoration of BRCA1 partially rescues from sensitivity to DZNep. (a) Detection of the human BRCA1 allele by PCR amplification of exon 11 in the 
reconstituted subclones KB1PR-3.12 E3 and F4. The human breast cancer cell line T47D was used as a positive control. (b) EZH2 protein levels of 
(untreated) KK14cre;Brca1F/F;p53F/F (KB1P), KB1PR and K14cre;Brca1w.t/w.t;p53F/F (KP) cell lines were analysed by western blotting. Correspond-
ing Ezh2 mRNA levels of KB1P, KB1PR and KP cell lines were measured by quantitative RT-PCR (shown as fold induction relative to Hprt). (c) Rep-
resentative growth inhibition curves for BRCA1-deficient cell lines (KB1P, in blue), BRCA1-proficient cell lines (KP, in red) and two clones of a 
BRCA1-reconstituted cell line (KB1PR E3 and F4, in purple) treated with 3-deazaneplanocin A (DZNep). A serial dilution of DZNep was added to 
the cells and cell viability was measured five days later (mean ± standard error of the mean). (d) EZH2 protein levels of hBRCA1-reconstituted 
KB1P cells 48 hours after treatment with DZNep or siRNAs targeting EZH2.Breast Cancer Research    Vol 11 No 4    Puppe et al.
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function of EZH2. Moreover, breast tumors in BRCA1-muta-
tion carriers show invariably loss of the other BRCA1 allele,
indicating that selection for loss of BRCA1 expression is not
achieved by high levels of EZH2. However, the observation
that these two basal-like breast cancer cell lines are also sen-
sitive to EZH2 inhibition, and the repeated observation that
EZH2 overexpression characterizes basal-like breast tumors,
warrants the further investigation of EZH2 as a druggable tar-
get.
Unfortunately, our preliminary in vivo studies with DZNep
revealed substantial toxicity in mice (data not shown). We are
currently investigating whether this is due to a dependence of
certain normal cell types on EZH2 expression, or whether this
is due to chemical properties of DZNep. The former would
complicate EZH2 inhibition as therapeutic strategy in breast
cancer, whereas the latter may be resolved by using other
EZH2 inhibitors or DZNep-analogs, which are currently being
developed. In addition, although DZNep inhibits sphere-forma-
tion of BRCA1-deficient tumor cells and considering the role
of EZH2 in stem cells and cancer [43], in vivo studies will be
required to determine whether targeting of EZH2 by itself or in
combination with other treatments can result in complete erad-
ication of the tumor.
Conclusions
The preclinical studies and clinical trials with combinations of
platinum drugs and Poly(ADP-ribose) polymerase (PARP)
inhibitors against BRCA1-mutated breast cancers constitute
one example of how insight into the genetic make-up of a
tumor subtype can provide a targeted and possibly more effec-
tive treatment [34,44]. Our data show that BRCA1-deficient
tumor cells are selectively dependent on EZH2 expression,
and suggest that pharmacological disruption of EZH2 could
provide another individualized approach for the treatment of
BRCA1-mutated breast cancers, and possibly also for spo-
radic basal-like breast tumors.
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IC50 values of DZNep on BRCA1-deficient vs. BRCA1-
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BRCA1-proficient
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deazaneplanocin A (DZNep) for the K14cre;Brca1F/F;p53F/F (KB1P) 
lines were compared with average IC50 values of the KB1P lines. 
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